Systemic high dose interleukin-2 (IL-2) postconditioning has long been utilized in boosting the efficacy of T cells in adoptive cell therapy (ACT) of solid tumors. The resulting severe off-target toxicity of these regimens renders local production at the tumor an attractive concept with possible safety gains. We evaluated the efficacy and safety of intratumorally administered IL-2-coding adenoviruses in combination with tumor-infiltrating lymphocyte therapy in syngeneic Syrian hamsters bearing HapT1 pancreatic tumors and with T cell receptor transgenic ACT in B16.OVA melanoma bearing C57BL/6 mice. The models are complementary: hamsters are semi-permissive for human oncolytic adenovirus, whereas detailed immunological analyses are possible in mice. In both models, local production of IL-2 successfully replaced the need for systemic recombinant IL-2 (rIL-2) administration and increased the efficacy of the cell therapy. Furthermore, vectored delivery of IL-2 significantly enhanced the infiltration of CD81 T cells, M1-like macrophages, and B-cells while systemic rIL-2 increased CD25 1 FoxP31 T cells at the tumor. In contrast with vectored delivery, histopathological analysis of systemic rIL-2-treated animals revealed significant changes in lungs, livers, hearts, spleens, and kidneys. In summary, local IL-2 production results in efficacy and safety gains in the context of ACT. These preclinical assessments provide the rationale for ongoing clinical translation.
With the field of cancer immunotherapy rapidly expanding, several strategies aiming to activate the immune system for effective tumor lysis and antitumor protection are emerging. [1] [2] [3] [4] [5] Among these strategies, adoptive cell transfer (ACT) using either ex vivo amplified and activated tumor-infiltrating lymphocytes (TIL) or gene modified T cells from the periphery have provided strong proof-of-concept data. However, routine use has been limited to few specialized centers. 1, 6 Unlike other therapies, ACT allows a patient-tailored treatment using autologous T cells that recognize tumor antigens and successfully lyse malignant cells. 6 The success of this approach in metastatic melanoma relies partly on a potent immunostimulatory molecule called interleukin-2 (IL-2), initially described as T cell growth factor. 6, 7 The most widely studied ACT approach, TIL therapy, provides long-term efficacy in about half of melanoma patients treated, [1] [2] [3] [4] [5] [6] 8, 9 and seems to work also in other tumor types. 10 Of note, high response rates are only achieved when high dose systemic IL-2 is given as postconditioning. 3 While TILs per se are extremely well tolerated, 8 postconditioning IL-2 causes high toxicity. 3, 9, 11 If the graft-stimulating effects of IL-2 could be retained, while reducing side-effects which derive from normal organs, ACT might become more widely used. This could provide much-needed treatment options to patients with cancer currently incurable.
IL-2 is a potent cytokine that promotes activation, proliferation and persistence of cytotoxic CD81 T cells and natural killer cells, and thus non-specifically stimulates the immune system against cancer. 12 Since its approval by the US Food and Drug Administration for metastatic melanoma and renal carcinoma, 13, 14 high dose IL-2 regimens have been administered to cancer patients either as monotherapies or as adjuvant treatments with other therapies. In ACT regimens, the immunostimulatory properties of IL-2 are utilized to boost the effectiveness of the T cell graft. 6, 7, 12, 15 Due to low accumulation in solid tumors 16 and a very short half-life, 17 IL-2 is given generally at high systemic doses in human ACT protocols. 3, 8, 9, 11 This causes dose-limiting serious adverse events such as vascular leakage syndrome, 11 kidney and liver dysfunctionalities 18 and even mortality. 19 Consequently, several approaches have been evaluated to overcome the problem of systemic toxicity and efficacy. For example, optimized doses, 20, 21 coupling to monoclonal antibodies 22 or even arming nonreplicating viruses 23 have been tried. However, none of these have been able to replace high dose recombinant IL-2 as the standard therapy or as postconditioning regimen in ACT protocols. Adenoviruses can be engineered to produce IL-2 locally, resulting in high tumor concentrations with low systemic exposure. 24 Non-replicating IL-2 coding adenoviruses have been found safe in humans and proof-of-concept efficacy has been observed in one phase I trial, but generally single-agent clinical efficacy of this approach has been less than satisfactory. 23, [25] [26] [27] Factors limiting the clinical efficacy of this approach include (i) the low tumor transduction that results from use of a conventional replication deficient vector, 28 (ii) low gene delivery to tumor cells deficient in the adenovirus type 5 receptor, (iii) low numbers of T cells able to recognize the tumor, (iv) unwanted immunological consequences of IL-2 in certain subsets in the tumor microenvironment (i.e., effects on CD25 1 FoxP31 regulatory T cells). 29 Many of these issues could be solved by using a replication competent virus which both lyses tumors cells, amplifies locally and enters tumor cells through a receptor not down-regulated in advanced cancer. 30 In this study, we treated solid tumors with ACT and compared the preclinical efficacy and safety of IL-2-armed adenoviruses with systemic administration of recombinant IL-2 (rIL-2). In both mice and hamsters, the adenovirus encoding IL-2 successfully replaced the need for systemic administration of rIL-2. Similarly as in humans, extensive tissue changes were seen in animals that were administered rIL-2, while this was not seen in adenovirus-treated animals. The safety and efficacy of adenovirally delivered IL-2 in combination with ACT is now being tested in a clinical trial.
Material and Methods

Cell lines and viruses
Hamster HapT1 pancreatic cell line (a kind gift from Dr. Hernandez-Alcoceba, University of Navarra) and the mouse B16.OVA melanoma cell line (a kind gift from Professor Richard Vile, Mayo Clinic) were cultured under optimal conditions. Replication deficient Ad5-CMV-mIL2, oncolytic Ad5/ 3-E2F-d24, and Ad5/3-E2F-d24-hIL2 were constructed as previously described.
24,31
Animal experiments
Two complementary models were used: hamsters are semipermissive to human oncolytic adenoviruses, 32 while mice are nonpermissive but allow detailed immunological analyses. 24, [33] [34] [35] All animal protocols were reviewed by the experimental animal committee of the University of Helsinki (Helsinki, Finland) and the Provincial Government of Southern Finland. 5-6 week old immunocompetent golden Syrian male hamsters (Envigo) received subcutaneous HapT1 tumors in both flanks (4 3 10 6 cells per tumor). After 7 days (when tumors reached 0.3 cm), the hamsters were randomized in groups (n 5 6). When the treatments started, tumors were measured with a digital caliper and followed during 19 days. Upon sacrificing the hamsters, blood serum, tumors and selected organs were collected for further characterization of immune cells and signs of toxicity. Alternatively, when treatments started, animals were followed during 5 days and upon sacrificing, tumors were collected for RNA extraction (n 5 3).
What's new?
While cancer immunotherapy with tumor-infiltrating lymphocytes is promising, the systemic application of high doses of interleukin-2 (IL-2) necessary for lymphocyte proliferation in solid tumors is often highly toxic. Here, the authors show that tumor-selective production of IL-2 from an oncolytic adenovirus successfully replaced the systemic application and improved the efficacy and safety of adoptive cell therapy in two complementary animal models. These results form the basis for a phase I clinical trial in melanoma patients.
Similarly, 4-6 week old immunocompetent C57BL/6 female mice (Harlan Laboratories) received 0.25 3 10 6 B16.OVA cells per tumor in the right flank. The mice were randomized in groups (n 5 8-10) on Day 10 after tumor cell implantation (tumors reaching 0.5 cm). Tumors were measured with a digital caliper and followed for 13 days during the treatments. Mice were sacrificed and their blood serum, tumors, and selected organs were collected for characterization of immune cells and signs of toxicity. Due to the fact that tumor size limit was reached in untreated mice, these were sacrificed 9 days after treatment. Tumor volume was calculated as 0.52 3 length 3 width 
Virus and cytokine treatments
Animal-free recombinant human IL-2 (rhIL2; #AF-200-02, PeproTech) and murine IL-2 (rmIL-2; #AF-212-12, PeproTech) were used in animal experiments. Hamsters received PBS as a vehicle control or a total of 15 doses of rhIL-2 (500,000 IU per injection per hamster) in blocks of 5 consecutive intraperitoneal injections (one per day), during 3 weeks. Likewise, mice received PBS as a vehicle control or a total of 10 doses of rmIL-2 (100,000 IU per injection per mice) in blocks of 5 consecutive intraperitoneal injections (one per day), during 2 weeks. At the same time the cytokine treatment started, other treatment groups were administered intratumorally once-a-week with oncolytic Ad5/3-E2F-d24-hIL2 (hamsters) or replication deficient Ad5-CMV-mIL2 (mice) at 1x10 8 VP/tumor in PBS. The oncolytic Ad5/3-E2F-d24 (hamsters) was administered only once at 1x10 8 VP/ tumor in PBS for the RNA extraction experiments. Animals that did not receive virus or cytokine treatments are regarded as untreated, and constitute the vehicle-control groups that were injected intratumorally or intraperitoneally with PBS.
Adoptive cell transfer
To grow TILs from hamsters, subcutaneous HapT1 tumors were grown for 10 days. As described previously, 32 excised tumor fragments of 1-3 mm 3 were cultured in GRex10 (80040S, Wilson Wolf) in complete RPMI supplemented with 3,000 IU/mL of rhIL-2. 32 Following 5 days of culturing, half of the medium was replaced with fresh medium supplemented with 6,000 IU/ml of rhIL-2 and 1 mg/mL of ConA (C0412, Sigma-Aldrich). Medium was refreshed every other day until the tumor implantation day. One day after the virus and cytokine treatments started, hamsters were injected intratumorally with 4 3 10 6 TIL. For mouse experiments with gene modified OVA specific T cells (OT-I cells), were obtained according to procedures previously described. 24 Briefly, splenocytes from OT-I TCR transgenic mice (003831, The Jackson Laboratory) were enriched for CD8a1 cells using a mouse CD8a1 T cell Isolation Kit (130-104-075, Miltenyi Biotec). Upon culturing under recommended conditions, 1 3 10 6 OT-I cells were injected intraperitoneally in mice that received virus or cytokine treatment one day before.
Cytokine expression profiles of the tumors
Cytokines were measured from snap-frozen processed mouse tumor samples and serums as previously described. 34 The level of IL-2, IL-6, IFNg and TNFa was determined using CBA mouse Th1/Th2/Th17 kit (560485, BD biosciences). The results were normalized to the total protein content of the sample.
Histopathology
Tissue samples from heart, lungs, liver, spleen, and kidney were collected, fixed in 10% formalin for 48 hr and preserved in 70% ethanol until further paraffin embedding. Hematoxylin and eosin stainings were performed in 4-5 mm thickness sections cut from the paraffin blocks. Histological changes were evaluated by a veterinary pathologist.
Reverse transcription quantitative PCR
Day 5 samples from excised hamster HapT1 tumors (30 mg) preserved in RNAlater stabilization reagent (Qiagen, 76104) were processed to yield a single-cell suspension 1 3 10 7 cells. Once lysed, the total RNA was extracted by passing the cell homogenate through a column in a series of washing steps using the protocol provided by RNeasy mini kit (Qiagen, 74104). Following the elution of hamster RNA, we synthetized cDNA using QuantiTect Reverse Transcription Kit (Qiagen, 205311) protocol. Briefly, we eliminated the genomic DNA and synthetized the cDNA using a reverse transcriptase and primer mix to ensure that all the RNA was reversely transcripted to cDNA. The quantitative PCR (qPCR) targeting hamster IL-2 was done using primers hamIL2-
0 and GAPDH-probe: (6FAM-)CAAGA GTGACT CCCACTCTTCCACCTTTGA(TAMRA)]. The qPCR conditions were set up as described previously. 36 
Flow cytometry
Tumor cell samples were prepared and analyzed according to the protocols previously established. 24, 32, 34 The antibodies used to stain hamster tumor samples were anti-CD8b PE (12-0080-82, eBiosciences) and anti-CD4 APC (17-0041-82, eBiosciences).The antibodies used to stain mouse tumor samples were anti-CD3 PE-Cy7 (560591, BD Biosciences), antiCD8b FITC (11-0083- 
Statistical analysis
Statistical tests were performed with GraphPad Prism version 7.01 (GraphPad Software) and SPSS version 24 (SPSS IBM
Results
Local production of IL-2 can replace systemic delivery in the context of TIL therapy
We first sought to investigate whether a serotype 5/3 chimeric oncolytic virus coding for human IL-2 (Ad5/3-E2F-d24-hIL2) could replace the need for exogenous recombinant human IL-2 (rhIL-2), which is highly toxic when used in cancer patients as a high dose postconditioning. Immunocompetent Syrian hamsters bearing HapT1 tumors were treated with TIL therapy in combination with either rhIL-2 or with Ad5/3-E2F-d24-hIL2. Interestingly, the intratumoral administration of oncolytic adenovirus was able to replace the need for exogenous IL-2 without inducing hamsterderived IL-2 ( Fig. 1a and Supporting Information Fig. S1 , respectively). Moreover, individual tumor growth curves from HapT1 tumors treated with TIL and Ad5/3-E2F-d24-hIL2 suggest that better tumor control is achieved since no tumor escape was seen (Fig. 1b) . These results suggest that the Ad5/ 3-E2F-d24-hIL2 is a promising agent to replace systemic rhIL-2 in TIL therapy.
Tumor-targeted IL-2 production enhances the antitumor efficacy of adoptively transferred OT-I cells
To extend the findings from adoptive TIL therapy to gene modified ACT, a more modern embodiment of the approach, we treated immunocompetent B16.OVA bearing mice with OVA-specific T cells and either with intratumoral replication deficient serotype 5 adenovirus coding for mIL-2 (Ad5-CMV-mIL2) or intraperitoneal recombinant mIL-2 (rmIL-2; Fig. 2a) . Following intratumoral injections of Ad5-CMVmIL2, superior efficiency in tumor rejection was seen when compared to systemic rIL-2 (Ad5-CMV-mIL2 1 OT-I versus rmIL-2 1 OT-I, p < 0.0001; Fig. 2a ).
Biodistribution of IL-2 following vectored intratumoral delivery
The utility of IL-2 for tumor control and enhancement of ACT results from local effects at the tumor, while adverse events follow from systemic exposure to normal organs. Therefore, it is appealing that high local concentrations at the tumor were observed with vectored delivery of IL-2, while systemic exposure was limited (Ad5-CMV-mIL2 1 OT-I tumor vs. rmIL-2 1 OT-I, p < 0.05; Fig. 2b ). In contrast, treatment with systemic rIL-2 did not result in similar levels in the tumor, despite histological changes being induced in normal organs, underlining the poor bioavailability of systemic rIL-2. The difference in IL-2 tumor concentration was 94-fold between vectored and systemic delivery (Fig. 2b) .
Intratumorally produced IL-2 promotes infiltration of TIL
To assess the associated immunological events, tumors of treated hamsters were collected and analyzed with flow cytometry. A higher percentage of CD41 cells was seen in animals that underwent systemic administration of rhIL-2 (Fig. 3a) . Intriguingly, the IL-2-armed oncolytic adenovirus increased the infiltration of CD81 cells (p < 0.05, Fig. 3b ).
Locally produced IL-2 enhances T cell infiltration without increase in CD25 1 FoxP31 T cells
The immune cell repertoire infiltrating the tumor milieu was characterized in order to gain insight into the mechanisms of action behind the improved antitumor efficacy of the combination of Ad5-CMV-mIL2 and OT-I cell transfer. A similar increase in CD81 T cell infiltration was seen with both vectored and systemic rIL-2 delivery when compared with mice treated solely with OT-I (OT-I versus Ad5-CMVmIL2 1 OT-I, p < 0.05; OT-I versus rmIL-2 1 OT-I, p < 0.001; Fig. 3c ). However, while OVA-specific CD81 T cells were present in the tumor at similar percentages in all groups (Fig. 3d) , gp100-specific CD81 T cells were greatly decreased in systemically delivered IL-2 treated mice (Fig.  3e) . A marked increase was seen in intratumoral M1-like macrophages and B-cells of mice treated with IL-2-armed adenoviruses and OT-I cells (OT-I vs. Ad5-CMV-mIL-2 1 OT-I, p < 0.05; Figs. 3f and 3g) , suggesting that local IL-2 therapy may affect the immune cell composition of the tumor microenvironment. In addition, we analyzed the intratumoral levels of CD25 1 FoxP31 T cells as the effect of IL-2 on these has been a persistent concern in systemic IL-2-related immunotherapy. 29 Importantly, we observed that local delivery of IL-2 did not mobilize CD25 1 FoxP31 T cells from the systemic circulation and bone marrow into tumors. In contrast, a significant increase in these cells was observed with systemic rmIL-2 treatment (Ad5-CMV-mIL2 1 OT-I vs. rmIL-2 1 OT-I, p < 0.05; Fig. 3 h) .
Systemic administration of recombinant human IL-2 induces histological changes in many hamster and mouse organs
The safety of IL-2 administered either systemically (as is standard in ACT protocols) or locally as vectored delivery was evaluated by histological examination of samples from the spleen, liver, heart, kidney, and lungs of treated hamsters and mice (Fig. 4 and Table 1 ). These are the relevant organs for IL-2 mediated toxicity. 3, 7, 9, 11, [13] [14] [15] 17, 18, 20 When compared with other treatment groups, systemic rIL-2 administration resulted in adverse tissue changes in spleen, liver, and splenic ligament (Fig. 4 and Table 1 ). For example, an increase in multifocal extramedullary hematopoiesis was observed in the liver of systemically treated hamsters (Fig. 4a) . The same phenomenon was observed in the spleen and splenic ligament (Table 1) . Furthermore, necrosis and histiocytosis of the splenic ligament was also observed (Table 1) .
A similar situation was found in mice. OT-I cell transfer alone did not cause any changes. Mice treated with OT-I 1 Ad5-CMV-mIL2 displayed a mild increase in apoptotic splenic lymph nodules (Fig. 5a ). Resembling the reported findings of adenovirus in the human liver, 37 these results in mice may reflect the residual leakage of the virus from the tumor to the systemic circulation. Notably, the systemic administration of rmIL-2 caused a significant increase in perivascular, peribiliar, and multifocal lobular extramedullary hematopoiesis in spleen and livers. Thus, mice that received OT-I 1 rmIL-2 differed markedly from the other groups, underlining the toxicity of systemic IL-2 administration, as has been seen in humans. 3, 7, 9, 11 In addition to increased apoptosis in splenic lymph nodules, there was increased extramedullary hematopoiesis seen in the kidneys and lungs (Table 1 and Fig. 5a ).
Thickening of large blood vessels in lungs is caused by systemically administrated rmIL-2
Since systemic rIL-2, and its inflammatory sequelae, are known to affect blood vessels, 38 they were studied further. Histological stainings from the lungs of mice that were treated with rmIL-2 1 OT-I differed from other therapeutic groups (Fig. 5a ). In these stainings, the circumference of arteries appeared smaller, and the muscular wall was thickened and slightly hyalinized (Fig. 5a) . Consequently, the lumina were narrowed due to reactive endothelial cells (Fig.  5a ).
Systemic delivery of rmIL-2 triggers the release of proinflammatory cytokines in mouse serum
The histopathological changes in the lungs, are consistent with a systemic increase of pro-inflammatory markers present in the blood serum of mice that received rmIL-2 1 OT-I. These had higher serum levels of tumor necrosis factor alpha (TNFa; 1.36 3 10 24 pg/mg total protein), interleukin-6 (IL-6; 5.28 3 10 24 pg/mg total protein), and interferon gamma (IFNg; 3.01 3 10 24 pg/mg total protein) when compared with the Ad5-CMV-mIL2 1 OT-I treated mice (3.21 3 10 25 pg/mg, 3.03 3 10 25 pg/mg, and 5.67 3 10 26 pg/ mg, respectively; Fig. 5b ). The serum level of TNFa in mice which received rmIL-2 1 OT-I was significantly increased over the group that received IL-2-armed adenoviruses (Ad5-CMV-mIL2 1 OT-I vs. rmIL-2 1 OT-I, p < 0.01) (Fig. 5b) . To summarize, contrasting with the systemic delivery of rmIL-2, local delivery of IL-2 at the tumor did not increase systemic levels of proinflammatory cytokines.
Discussion
Clinical experience has clearly outlined the dual effects of systemic high dose IL-2. When combined with ACT in conditioning regimens in metastatic melanoma, postconditioning with high dose IL-2 increases efficacy but is accompanied with adverse events. 3, 7, 9, 11 From a safety perspective, adenoviral vectorization of immune modulatory cytokines is a well-tolerated approach for overcoming off-target adverse events. 4, 23, 24, 27, 35, 39 However, this approach has limited clinical efficacy as a single agent. 22, 23, 25, 27 The unique ability of adenoviruses to enhance ACT was recently discovered and the mechanism of action was dissected. 4, 24, 31, 33, 35, 40 However, it was previously unknown if systemic IL-2 should still be used in clinical protocols where oncolytic adenoviruses are used to unleash the full potential of ACT in the context of solid tumors. While there is no disagreement that IL-2 is beneficial for TIL therapy, it has not been previously been studied if its local production can replace traditional systemic administration. Here, we found that systemic IL-2 may not be necessary, as adenoviral production of IL-2 can achieve the same graft-stimulating effects. Not only was local delivery noninferior, conversely it resulted in superior efficacy over systemic IL-2. Moreover, tissue level analyses revealed attractive immunological changes caused by the virus and high local IL-2 concentrations.
Many studies suggest that the systemic use of recombinant IL-2 can hamper the anti-tumor efficacy by stimulating CD25 1 FoxP31 T cells. 7, 12, 24, 29 Therefore, the significant increase in this subset can partly explain the dampened T cell response in B16.OVA tumors from animals treated with systemic recombinant IL-2. In addition, the observed lack of Bcells (CD191) in this group may illustrate the reported dependence of these cells for an optimal CD8/CD4 anti-tumor response in the B16 melanoma tumor model. 24, 41 The lack of cross-reactive antibodies, however, prevented us from assessing the CD25 1 FoxP31 T cells and other immune phenotypes in hamster HapT1 tumors. This is a general problem with more exotic models: reagents that would allow analyses as profound as possible in mice are just not available.
However, the hamster model has utility. Its semipermissive nature with regard to adenovirus replication allowed us to study the efficacy of the intratumoral delivery of IL-2 in the presence of oncolysis. 31, 32 Our data suggests that the high antitumor efficacy in animals treated with IL-2-armed oncolytic adenovirus may be explained by the documented release of tumor-associated antigens 33, 34, 42 and virus-mediated danger signals. 43 Complementary data from adenovirus-treated B16.OVA mouse tumors demonstrated a significant increase in M1-like macrophages (CD86 1 CD11b 1 F4/801). Similarly, recent phase I clinical trial data showed that increased macrophage polarization may be affected following oncolytic adenovirus treatment. 39 In line with this proposal, our results suggest a possible link between macrophage polarization and adenovirus treatment due to the reported macrophage expansion mediated by adenovirus-induced interferons. 44 The upregulation of CD86 on these potential antigen presenting cells may have induced T cell activation, thus resulting in a higher anti-tumor activity. The outcome of these results, are similar with the reported elevated levels of effector T cells in mice bearing B16 tumors and treated with anti-CTLA-4, an antibody that also binds CD86. 45 In accordance with human data from melanoma patients treated with ACT, the administration of high-dose systemic recombinant IL-2 results in off-target effects in numerous normal tissues. 19 Our data from the B16.OVA tumor model with IL-2-armed adenovirus suggests tumor-restricted IL-2 production with negligible blood serum leakage, consequently avoiding side-effects in vital organs. In contrast, concerning effects were observed in conjunction with systemic rIL-2 administration. In particular, we suspect that the inflammatory effects of systemic rIL-2 caused extramedullary hematopoiesis, mainly in the liver and spleen. This was seen in both mice and hamsters. It has been proposed that abnormal myelocytic and lymphoid proliferation outside of the bone marrow constitutes a response to maintain homeostasis similar to the one found in common g-chain deficient mice. 46 Noteworthy, most of the marked extramedullary hematopoiesis in the organs is from myeloid progeny confirming the known involvement of IL-2 in myelopoiesis. 47 The effects of high-dose systemic IL-2 were profound, triggering the remodeling of the arterial musculature of the lungs in mice. Endothelial cells underlying thickened arteries in these animals suggest that they might have been responsive to the increased systemic levels of IL-2-induced proinflammatory cytokines, such as IL-6 and TNFa. IL-6 has been correlated with arterial stiffening, 48 while depletion of systemic T cell-derived TNFa in mice prevents vascular dysfunction. 49 Blood serum upregulation of IL-6, TNFa, and The degree of tissue changes was ranked in the following manner: -absent changes; 1 minimal changes; 11 moderate changes; 111 marked changes. This scoring system is based on observations found in the tissue. IFNg, most likely produced by IL-2-induced T cells, 12,38 is a common feature of the systemic infusion of IL-2 in mice 50 as well as in human patients. 18 Overall, the preclinical assessment we have performed here, seems to demonstrate a clear advantage to local delivery of IL-2 over conventional systemic IL-2 postconditioning in the context of solid tumor T cell therapy. Converting the tumor microenvironment into one producing IL-2 through adenoviral delivery, was associated with a significant improvement in efficacy and, perhaps more importantly, in safety. In conventional ACT protocols, and TIL protocols in particular, much of the toxicity has been due to IL-2. 3, 7, 9, 11 TILs themselves have been well tolerated, resulting only in mild flu-like symptoms, chills and fever. 8 Vectored delivery of IL-2 from an oncolytic adenovirus platform is now being explored in a phase I clinical trial sponsored by TILT Biotherapeutics Ltd. Melanoma patients receiving TIL treatment will also be injected intratumorally with TILT-123, an oncolytic adenovirus expressing hIL-2 and hTNFa.
